Sarepta Therapeutic (SRPT) PT Raised to $47 at Baird; Increasingly Bullish on Risk/Reward
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta Therapeutic (SRPT) PT Bumped to $35 at RBC Capital
August 7, 2015 8:21 AM EDTRBC Capital analyst Simos Simeonidis reiterated a Sector Perform rating and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $35.00 (from $20.00) to account for the potential value of eteplirsen's follow-on exon programs.
Simeonidis commented, "Sarepta updated investors on the progress of... More
SunTrust Downgrades Sarepta Therapeutic (SRPT) to Neutral
August 7, 2015 7:07 AM EDTSunTrust Robinson Humphrey downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Neutral with a price target of $33 (unchanged).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $34.63 yesterday.
... MoreSarepta Therapeutics (SRPT) Tops Q2 EPS by 20c
August 6, 2015 7:35 AM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.01), $0.20 better than the analyst estimate of ($1.21).
We made significant achievements from both a regulatory and clinical perspective this quarter and look to build on this momentum as we continue through the regulatory process for eteplirsen,... More
